FIGURE 1





Figure 2







Figure 4A






Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 5E




Figure 5F





Figure 6A






Figure 7A




Figure 7B




Figure 8A




Figure 8B





Fig. 9



Selectivity Threshold Modifiers

40000

Cell line 1 1% TFA 0.1 M sodium acetate pH 4.5 20 mM imidazole PBS 0.1% Tween20 PBS + 3 M urea 0.1% Tween20 PBS

**PBS** 

30000

20000 Mass/Charge

10000

Figure 10A

Figure 10B




Figure 10C




Figure 10D







Figure 12

1st dimension: Isoélectric focusing



2nd dimension: SDS PAGE









FIG. 16






Fig. 18








FIG. 19









Normalized	marker	nante aran	(marker/internal	۵٤۵۱۰
MOHIMANIZEU	marker	peak area	(marker/internal	sta):

71.05119

0.143227

Control	0.0
Disease	0.61
Drug treated	0.05

Retentate Map<sup>TM</sup> of Human Urine SELDI ProteinChip<sup>TM</sup> Array




FIG. 24





FIG. 25










FIG. 27







Binding in the presence of excess free receptor (---)

Fig. 27B

TGFβ (100 ng/ml 2.5xconditioned medium)








Figure 30




Figure 31




Figure 32





Fig. 33A

Fig. 33B

FIG. 33



Mass/charge